SCHEMBL1107147

SCHEMBL1107147

Cc1ccc(C(=O)OCCN(C)C)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHLPP2 Q6ZVD8 1/20 0.73
ALDH1A1 P00352 3/20 0.65
MAPT P10636 2/20 0.65
GAA P10253 1/20 0.59
LMNA P02545 3/20 0.58
MAOA P21397 2/20 0.58
HRH3 Q9Y5N1 2/20 0.58
SCN1A P35498 2/20 0.58
SCN2A Q99250 2/20 0.58
SCN3A Q9NY46 2/20 0.58
CYP1A2 P05177 1/20 0.58
CNR1 P21554 1/20 0.58
DRD4 P21917 1/20 0.58
ACHE P22303 1/20 0.58
HRH2 P25021 1/20 0.58
HTR2A P28223 1/20 0.58
HTR2C P28335 1/20 0.58
MAPK1 P28482 1/20 0.58
NTSR1 P30989 1/20 0.58
HRH1 P35367 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8963488 0.93 PHLPP2 (0.83) PHLPP2ALDH1A1MAPTGAALMNA
SCHEMBL14924442 0.90 GAA (0.74) PHLPP2ALDH1A1MAPTGAALMNA
SCHEMBL8639938 0.86 PHLPP2 (0.73) PHLPP2ALDH1A1MAPTGAALMNA
SCHEMBL8963375 0.86 PHLPP2 (0.73) PHLPP2ALDH1A1MAPTGAALMNA
SCHEMBL14947119 0.85 PHLPP2 (0.54) PHLPP2ALDH1A1MAPTGAALMNA
SCHEMBL206554 0.85 TDP1 (0.61) ALDH1A1MAPTGAALMNAMAOA
SCHEMBL10777193 0.84 PHLPP2 (0.71) PHLPP2ALDH1A1MAPTGAALMNA
SCHEMBL1701017 0.84 PHLPP2 (0.71) PHLPP2ALDH1A1MAPTGAALMNA
SCHEMBL8487897 0.84 PHLPP2 (0.71) PHLPP2ALDH1A1MAPTGAALMNA
SCHEMBL4835480 0.84 PHLPP2 (1.00) PHLPP2ALDH1A1MAPTGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180071367-A1 METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION OXEIA BIOPHARMACEUTICALS, INC. (US) 2018-03-15 US disclosed
US-20170281732-A1 METHODS OF TREATING MILD BRAIN INJURY OXEIA BIOPHARMACEUTICALS, INC. (US) 2017-10-05 US disclosed
US-20170281732-A1 METHODS OF TREATING MILD BRAIN INJURY OXEIA BIOPHARMACEUTICALS, INC. (US) 2017-10-05 US disclosed
US-20170266257-A1 METHODS OF TREATING TRAUMATIC BRAIN INJURY OXEIA BIOPHARMACEUTICALS, INC. (US) 2017-09-21 US disclosed
US-20170121385-A1 METHODS OF TREATING NEURODEGENERATIVE CONDITIONS OXEIA BIOPHARMACEUTICALS, INC. (US) 2017-05-04 US disclosed
US-8153660-B2 Piperidyl-propane-thiol CCR3 modulators BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-10 US disclosed
US-20100317634-A1 PIPERIDYL-PROPANE-THIOL CCR3 MODULATORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-16 US disclosed
US-20080234283-A1 Glutathione peroxidase mimetics for treatment of neurodegenerative, pulmonary and inflammatory diseases RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) 2008-09-25 US disclosed
US-20080213785-A1 Method of predicting a benefit of antioxidant therapy for prevention or treatment of vasclar disease in hyperglycemic individuals BBDX, INC. 2008-09-04 US disclosed
US-20080207679-A1 Glutathione peroxidase mimetics for the treatment of dermatoses BERKOWITZ NOAH 2008-08-28 US disclosed
WO-2008100629-A2 GLUTATHIONE PEROXIDASE MIMETICS FOR THE TREATMENT OF DERMATOSES SYNVISTA THERAPEUTICS, INC. (US) 2008-08-21 WO disclosed
US-5863913-A ALLEVIATION OF RENAL DYSFUNCTION WITHOUT AFFECTING BLOOD PRESSURE AT A LOW BLOOD CONCENTRATION. KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) 1999-01-26 US disclosed
EP-0002625-B1 PHOTOCURABLE COMPOSITIONS, PHOTOACTIVATOR- PHOTOINITIATOR COMBINATIONS USEFUL THEREIN AND METHOD OF MAKING CURED PLASTICS COMPOSITIONS THEREFROM WARD BLENKINSOP AND COMPANY LIMITED (GB) 1982-05-12 EP disclosed
EP-0002625-A1 Photocurable compositions, photoactivator- photoinitiator combinations useful therein and method of making cured plastics compositions therefrom WARD BLENKINSOP AND COMPANY LIMITED (GB) 1979-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170266257-A1 METHODS OF TREATING TRAUMATIC BRAIN INJURY ATP6V1B2, FABP7, GHSR PHLPP2 642/4885ALDH1A1 4000/4885MAPT 1278/4885
US-20080234283-A1 Glutathione peroxidase mimetics for treatment of neurodegenerative, pulmonary and inflammatory diseases GPX1, GPX4, MPO PHLPP2 1131/4885ALDH1A1 1010/4885MAPT 461/4885
US-20100317634-A1 PIPERIDYL-PROPANE-THIOL CCR3 MODULATORS CCR3, CCR1, CCRL2 PHLPP2 1272/4885ALDH1A1 583/4885MAPT 3205/4885
US-20080207679-A1 Glutathione peroxidase mimetics for the treatment of dermatoses GPX1, GPX4, GGT1 PHLPP2 791/4885ALDH1A1 408/4885MAPT 3190/4885
US-20170121385-A1 METHODS OF TREATING NEURODEGENERATIVE CONDITIONS HTT, SNCA, NLN PHLPP2 766/4885ALDH1A1 3893/4885MAPT 31/4885
US-20180071367-A1 METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION CRH, PYGB, CHAT PHLPP2 548/4885ALDH1A1 4652/4885MAPT 354/4885
US-20170281732-A1 METHODS OF TREATING MILD BRAIN INJURY ATP6V1B2, GHSR, CRH PHLPP2 505/4885ALDH1A1 3892/4885MAPT 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.